Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hutchmed China Ltd ADR (NQ: HCM ) 17.26 -0.63 (-3.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hutchmed China Ltd ADR < Previous 1 2 3 4 5 6 7 8 9 Next > HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia August 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Hutchmed scores U.S. success with cancer drug, but profits still dip August 15, 2024 Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs... Via Benzinga HUTCHMED Reports 2024 Interim Results and Provides Business Updates July 31, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Why HUTCHMED Stock Is Moving Higher Friday July 05, 2024 HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status. Via Benzinga HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status July 03, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED to Announce 2024 Half-Year Financial Results June 26, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 June 24, 2024 — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology June 16, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China June 06, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine June 02, 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting May 23, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees May 17, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress May 16, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China May 13, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui May 13, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday May 09, 2024 Via Benzinga HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee May 08, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda April 26, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion April 06, 2024 ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... Via Talk Markets HUTCHMED Highlights Data to be Presented at AACR Congress 2024 April 05, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status April 02, 2024 From HUTCHMED (China) Limited Via GlobeNewswire HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC March 27, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session March 14, 2024 U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 13, 2024 Via Benzinga Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket March 13, 2024 Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results. Via Benzinga Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 13, 2024 Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 13, 2024 Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning! Via InvestorPlace Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session March 13, 2024 U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Via Benzinga HUTCHMED Reports 2023 Full Year Results and Provides Business Updates February 28, 2024 From HUTCHMED (China) Limited Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.